Kyverna Therapeutics (KYTX) Other Working Capital Changes (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Other Working Capital Changes data on file, last reported at -$503000.0 in Q1 2026.

• Quarterly Other Working Capital Changes rose 47.77% year-over-year to -$503000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.9 million (down 1.3% YoY) and the FY2025 annual result came in at -$3.3 million, down 39.18% from the prior year.
• Other Working Capital Changes advanced to -$503000.0 in Q1 2026, from -$3.3 million in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $2.6 million in Q1 2024 to a low of -$3.1 million in Q2 2024.
• A 4-year average of $133384.6 and a median of $380000.0 in 2025 frame the typical range for Other Working Capital Changes.
• The widest YoY moves for Other Working Capital Changes: up 377.13% in 2025, down 416.07% in 2025.
• Tracing KYTX's Other Working Capital Changes over 4 years: stood at -$463000.0 in 2023, then sank by 39.74% to -$647000.0 in 2024, then sank by 416.07% to -$3.3 million in 2025, then soared by 84.94% to -$503000.0 in 2026.
• The last three Other Working Capital Changes figures came in at -$503000.0 (Q1 2026), -$3.3 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.